MV Biotherepautics SA (from now on MVBio), a Swiss microbiome biotherapeutics company, today announced that Dr. Gabriel Haering has been named as CEO.
Haering has more than 20 years of senior management experience, including the last eleven years as Chief Executive Officer of Cerbios-Pharma SA, a privately held company with headquarter in Barbengo-Lugano, Switzerland, specializing in the development and manufacture of both chemical and biological APIs for its partners worldwide.
“Gabriel is the right leader for MVBio,” said Dr. Fabio Grassi, MVBio founder and Chairman of the Board.
“Gabriel’s extensive background in business development, strategy and organization skills will help MVBio to move into the next clinical stages and develop strategic alliances with investors and partners. We believe his strong leadership experience will help MVBio to move from the actual R&D stage to a real pharma company.”
“I am very excited to be joining MVBio and Fabio in particular,” said Gabriel Haering.
“I met Fabio beginning of this year as coach and got really excited about the results obtained on cancer immunotherapy and dysbiosis. I believe that MVBio patented technology and biotherapeutics will significantly improve the actual treatments and happy to help Fabio making his dream reality.”
As a founder of MVBio, Fabio Grassi is a leading expert in mucosal immunology. He earned his degree in Medicine at the University of Pavia and a Ph.D. in Microbiology at the University of Milan. He joined the Institute for Research in Biomedicine in Bellinzona in 2002 as Head of the Mucosal Immunology lab. His research is focused on understanding mechanisms regulating the mucosal adaptive immune response as well as mutualism with intestinal commensals.
During the last 10 years he was also involved with startups at different levels including board member of Lipidor (NASDAQ First North: LIPI.ST).
About MV BioTherapeutics
MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona.
The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications:
- ApyraVax®is a technology platform for live attenuated oral vaccines eliciting protective mucosal responses against enteric pathogens. The first application is a vaccine for Clostridioides difficile infection, a disease that is causing hundreds of thousands of casualties every year and generating huge medical costs.
- ApyraMed® is a live biotherapeutic that has been validated in pre-clinical studies as an enhancer of immune checkpoint blockade in cancer immunotherapy and as a modulator of antibiotic-induced dysbiosis.
Research experiments and preclinical trials are performed in the research lab hosted at IRB.